Drugs targeting GLS activity such as BPTES (bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3) or CB-839 have gained attention owing to their potent inhibition of GLS1 activity and anti-proliferative effect in multiple tumor subtypes including leukemia and triple negative breast cancer [11]. Here, GLS is linked to neoplasm.